Skip to main content
ARIX BIOSCIENCE PLC logo

ARIX BIOSCIENCE PLC — Investor Relations & Filings

Ticker · ARIX ISIN · GB00BD045071 LEI · 213800OVT3AHQCXNIX43 IL Financial and insurance activities
Open in API
Filings indexed 547 across all filing types
Latest filing 2024-01-04 Major Shareholding Noti…
Country GB United Kingdom
Listing IL ARIX

About ARIX BIOSCIENCE PLC

https://www.arixbioscience.com/

Arix Bioscience plc is a global venture capital company that specializes in the biotechnology and life sciences sectors. The firm's primary activity involves investing in and building innovative biotech companies, providing capital and strategic support from early stages, including seed, preclinical, and clinical development. Arix focuses on identifying and nurturing breakthrough advances in life sciences to accelerate the development of new medical technologies and therapies. According to public information, the company has entered into a process of liquidation.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is a 'TR-1: Standard form for notification of major holdings' filed with the FCA (Financial Conduct Authority) regarding Arix Bioscience PLC. Section 2 indicates this is a notification due to 'An acquisition or disposal of financial instruments'. Section 7 shows the resulting holding percentage (5.19%) crossing a threshold. The OAM Categories explicitly list '2.3. Major shareholding notifications'. This directly corresponds to the definition for Major Shareholding Notification (MRQ).
2024-01-04 English
Update regarding timing of Proposed Scheme of Reconstruction
Delisting Announcement Classification · 1% confidence The document is an 'Update regarding timing of Proposed Scheme of Reconstruction' between Arix Bioscience PLC and RTW Biotech Opportunities Ltd. It discusses the timing for sending out a Circular and notice of a general meeting, and the publication of a prospectus related to an all-share acquisition via a scheme of reconstruction and voluntary winding-up. This involves a significant corporate transaction (acquisition/merger) and subsequent shareholder/regulatory actions. Since the core subject is a proposed acquisition/takeover, the most appropriate category is M&A Activity (TAR). It is not a full 10-K, an ER, or a simple DIV announcement. It is a specific announcement about a major corporate transaction.
2023-12-22 English
Unaudited NAV for November 2023
Net Asset Value Classification · 1% confidence The document explicitly states 'Unaudited NAV for November 2023' and provides a table detailing the 'Total NAV' and 'NAV per share' as of 30 November 2023. This content directly corresponds to the definition of Net Asset Value (NAV) updates, which is classified under the code NAV.
2023-12-13 English
Portfolio Company Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial
Regulatory Filings Classification · 1% confidence The document is a press release issued by Arix Bioscience plc, announcing a milestone achieved by its portfolio company, Aura Biosciences (dosing the first patient in a Phase 3 trial). The text is structured like a standard corporate news announcement, dated December 8, 2023, and includes boilerplate language about forward-looking statements and contact information. Crucially, the end of the document states: "Dissemination of a Regulatory Announcement, transmitted by EQS Group." This indicates it is a general regulatory disclosure or news release. Since it is not a formal financial report (like 10-K or IR), nor a specific announcement like a dividend (DIV) or management change (MANG), and it is a general regulatory announcement disseminated via a service, the most appropriate fallback category is Regulatory Filings (RNS). The document length is moderate (11,608 chars), but its primary function is to disseminate news under regulatory requirements, not to be the detailed report itself.
2023-12-08 English
Correction: Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock
Share Issue/Capital Change Classification · 1% confidence The document is a correction notice regarding an announcement about a portfolio company (Aura Biosciences) closing a public offering. The text explicitly states it is a 'Correction' to a previous announcement and includes standard regulatory dissemination information ('Dissemination of a Regulatory Announcement, transmitted by EQS Group'). Since the content is an update/correction about a significant corporate event (financing/offering) that is not a standard periodic report (10-K, IR) or a specific management/director action, and it is disseminated via a regulatory news service (EQS), it fits best under the general 'Regulatory Filings' category, which serves as a fallback for miscellaneous regulatory announcements not covered by more specific codes like DIV, CAP, or DIRS. Given the nature of the announcement (a portfolio company's financing), it is a regulatory disclosure, but not a primary filing type listed. Therefore, RNS is the most appropriate classification.
2023-11-13 English
Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock
Share Issue/Capital Change Classification · 1% confidence The document is a brief announcement from Arix Bioscience plc regarding an action taken by its portfolio company, Aura Biosciences, specifically the closing of a $99 million public offering of common stock. The text is short (under 5,000 characters) and serves primarily to disseminate news about a financing event involving a related entity. This type of announcement, which details fundraising or capital structure changes, aligns best with the 'Capital/Financing Update' definition (CAP). Although it is an announcement, it is reporting a specific financial transaction rather than just announcing the publication of a separate, larger report, making CAP more specific than RPA or RNS.
2023-11-10 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.